Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Orlistat

W McNeely1, P Benfield

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 26, 1998
PubMed
Summary
This summary is machine-generated.

Orlistat, a pancreatic lipase inhibitor, aids weight loss in obese individuals. Clinical trials show orlistat significantly increases bodyweight reduction compared to placebo over one and two years.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Moclobemide: An update of its pharmacological properties and therapeutic use.

Drugs·2017
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Optical path clearing and enhanced transmission through colloidal suspensions.

Optics express·2010
Same author

Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002-2004.

Vector borne and zoonotic diseases (Larchmont, N.Y.)·2008
Same author

Interferon-beta-1a: A Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Obesity Research

Background:

  • Orlistat (tetrahydrolipstatin) functions as a pancreatic lipase inhibitor.
  • It is utilized in managing obesity by acting within the gastrointestinal lumen.
  • Orlistat has demonstrated effects on lipid profiles in obese patients.

Purpose of the Study:

  • To evaluate the efficacy of orlistat in promoting weight loss in obese patients.
  • To assess the impact of orlistat on body weight and body composition over extended periods.
  • To investigate changes in serum lipid levels during orlistat treatment.

Main Methods:

  • Clinical trials involving obese patients treated with orlistat or placebo.
  • Administration of orlistat at 360 mg/day for 12 weeks in some studies.

Related Experiment Videos

  • Longer-term studies (up to 2 years) with varying dietary conditions were conducted.

    • Main Results:

    • Orlistat treatment led to a significantly greater percentage of bodyweight loss compared to placebo (5% vs 3.5% in 12-week trials).
    • In 2-year studies, orlistat recipients showed greater weight loss by year 1, with further reduction or maintenance in year 2.
    • A higher proportion of orlistat patients achieved >5% or >10% initial bodyweight loss in both 1- and 2-year studies.

    Conclusions:

    • Orlistat is an effective pharmacological agent for promoting significant weight loss in obese individuals.
    • The weight loss benefits of orlistat are sustained over a 2-year period.
    • Orlistat treatment can lead to a greater proportion of patients achieving clinically meaningful weight loss targets.